Coefficient Bio
Category: AI in Healthcare
A biological foundation model startup specializing in generative AI for protein engineering and autonomous antibody design. Coefficient Bio was founded in 2023. The company is led by Aris Theologis. Based in New York, USA. Team size: 1-10. Total funding raised: Undisclosed. Latest round: Acquisition. Key investors include Dimension, Anthropic.
- Founded
- 2023
- Headquarters
- New York, USA
- Team size
- 1-10
- Total funding
- Undisclosed
Value proposition
Accelerates the discovery of novel therapeutics by using high-fidelity machine learning models to predict and design complex biological structures, significantly reducing the time and cost of traditional wet-lab experimentation.
Products and solutions
Biological Foundation Models (Large-scale models trained on genomic and proteomic data), Autonomous Antibody Design Platform, Generative Protein Engineering Suite, Computational Drug Discovery Pipeline
Unique value
The company was built by the core technical team from Genentech’s 'Prescient Design' unit, arguably the most elite computational drug discovery group in the industry, enabling a 'stealth-to-exit' cycle of only eight months.
Target customer
Pharmaceutical companies, biotechnology firms, and research institutions focused on drug discovery.
Industries served
Biotechnology, Pharmaceuticals, Healthcare AI, Life Sciences
Technology advantage
Leverages proprietary architectures for biological foundation models that bridge the gap between digital sequence design and physical biological function, specifically optimized for antibody therapeutics.
How they differentiate
Coefficient Bio differentiates through its 'Biological Foundation Models' (BFMs) and a team composed of the core technical lineage from Genentech’s elite Prescient Design unit. Unlike broader AI-drug discovery firms, they focus on high-fidelity generative models specifically for autonomous antibody design and protein engineering, validated by an extremely rapid 8-month stealth-to-exit cycle.
Main competitors
Generate:Biomedicines, Isomorphic Labs, Profluent Bio, EvolutionaryScale
Key partnerships
Anthropic (Parent company/Acquirer), Dimension (Lead Seed Investor), Genentech (Technical lineage and research origin)
Notable customers
Anthropic (Parent Company), Genentech (Technical Lineage/Research Origin)
Major milestones
Founded in 2023 by former Genentech and Evozyne executives, Secured Seed funding led by Dimension in late 2023, Acquired by Anthropic in April 2024 for approximately $400M to lead their 'AI for Science' initiatives
Growth metrics
Achieved a $400M exit valuation within approximately 8 months of founding; transitioned from stealth startup to a core division of a Tier-1 AI lab (Anthropic).
Market positioning
Elite AI-Biotech research unit and foundation model developer, now serving as the life sciences engine for Anthropic.
Geographic focus
North America (primarily New York and San Francisco)
Patents and IP
Proprietary IP related to generative protein design and antibody optimization (specific filings remain confidential under Anthropic's acquisition terms).
About Aris Theologis
Aris Theologis is a surgeon-scientist and business executive with an MD/MBA from Harvard. He previously served as the Chief Business Officer at Evozyne, a generative AI protein-design company, where he led significant fundraising and strategic partnerships. He is also a faculty member at Harvard Business School and completed his residency at UCSF.
Official website: https://coefficientbio.com/